Beta-cyclodextrin (BCD) (BCD)

Beta-cyclodextrin (β-CD) is a cyclic oligosaccharide consisting of seven D-glucose units linked by α-1,4-glycosidic bonds, characterized by a unique toroidal structure with a hydrophobic inner cavity and a hydrophilic outer surface [Wikipedia, 2024]. While traditionally classified as a pharmaceutical excipient used to enhance the solubility and stability of lipophilic drugs, it is increasingly recognized as an active therapeutic agent in its own right [NIH, 2023]. Its primary mechanism of action involves the formation of host-guest inclusion complexes, which allows it to sequester cholesterol and other lipids from biological membranes and lysosomes [PubMed, 2022]. This property is therapeutically exploited in the treatment of Niemann-Pick disease type C, where hydroxypropyl-β-cyclodextrin is used to mobilize accumulated cholesterol, and in atherosclerosis research to promote reverse cholesterol transport [MDPI, 2023]. Additionally, β-CD can disrupt lipid rafts, thereby interfering with viral entry and cellular signaling pathways [Frontiers, 2021]. Despite its broad utility, therapeutic applications are often limited by safety concerns such as dose-dependent nephrotoxicity and ototoxicity [NIH, 2024].

Other names

β-CyclodextrinCycloheptaamyloseSchardinger beta-dextrinCyclomaltoheptaoseβ-CD

Beta-cyclodextrin acts as a molecular host that forms non-covalent inclusion complexes with lipophilic guest molecules, thereby increasing their solubility and stability; it also sequesters cholesterol from biological membranes and lysosomes, disrupting lipid rafts and mobilizing lipid accumulations.